Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

78.85CHF
19 Sep 2017
Change (% chg)

CHF-0.40 (-0.50%)
Prev Close
CHF79.25
Open
CHF79.10
Day's High
CHF79.65
Day's Low
CHF78.55
Volume
31,763
Avg. Vol
63,681
52-wk High
CHF95.35
52-wk Low
CHF66.00

Select another date:

Tue, Sep 12 2017

BRIEF-Cardiome announces agreement with Basilea

* Cardiome announces agreement with Basilea for distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel

BRIEF-Basilea reports significant progress on partnering and development programs

* Basilea reports improved financial results in half-year 2017 driven by growing product sales; significant progress on partnering and development programs Source text for Eikon: Further company coverage:

BRIEF-Basilea Pharmaceutica H1 net loss narrows to CHF 20.6 million​

* ‍56 PERCENT INCREASE IN TOTAL H1 REVENUE, AMOUNTING TO CHF 46.2 MILLION​

BRIEF-Basilea completes license agreement with Pfizer for Cresemba

* BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT WITH PFIZER FOR ANTIFUNGAL CRESEMBA® FOR EUROPE, RUSSIA, TURKEY AND ISRAEL

BRIEF-Basilea announces license agreement with Pfizer for antifungal Cresemba

* Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey And Israel

BRIEF-Basilea announces distribution agreement with Avir Pharma for Cresemba And Zevtera in Canada

* BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH AVIR PHARMA INC. FOR CRESEMBA (ISAVUCONAZOLE) AND ZEVTERA (CEFTOBIPROLE) IN CANADA

BRIEF-Basilea Pharmaceutica awarded $54.8 mln of additional funding by BARDA

* BASILEA AWARDED USD 54.8 MILLION OF ADDITIONAL FUNDING BY BARDA TO SUPPORT PHASE 3 DEVELOPMENT OF CEFTOBIPROLE

BRIEF-Basilea Pharmaceutica announces clinical study agreement with Adult Brain Tumor Consortium

* BASILEA ANNOUNCES CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM TO EXPLORE BAL101553 IN NEWLY DIAGNOSED GLIOBLASTOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea Pharmaceutica ‍announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553

* ‍ANNOUNCES PRESENTATION OF INTERIM PHASE 1/2A CLINICAL DATA WITH ANTICANCER DRUG CANDIDATE BAL101553 AT ASCO MEETING​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Basilea shareholders approve resolutions proposed by the board at the general meeting of shareholders

* Basilea shareholders approve all resolutions proposed by the board of directors at the ordinary general meeting of shareholders

Select another date: